Citation

Tello K, Hoffmann A, Beutel B, Greulich T, Vogelmeier CF, Richter MJ, Kuhnert S, Böselt T, Alter P, Holland A, Idzko M, Buhl R, Koczulla AR. Respir. Med. Case Rep. 2019; 28.

Copyright

(Copyright © 2019, Elsevier Publishing)

DOI

10.1016/j.rmcr.2019.100927

PMID

unavailable

Abstract

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma. © 2019 The Authors

Language: en

Keywords

adult; human; suicide; female; Asthma; case report; C reactive protein; clinical article; hospital admission; tricyclic antidepressant agent; unclassified drug; priority journal; quetiapine; intensive care unit; drug withdrawal; asthma; computer assisted tomography; artificial ventilation; Glasgow coma scale; magnesium; ibuprofen; positive end expiratory pressure; Article; drug substitution; prednisolone; respiratory acidosis; budesonide; tiotropium bromide; sultamicillin; lung infiltrate; meropenem; eosinophil; budesonide plus formoterol; sulbactam; Intensive care medicine; ipratropium bromide plus salbutamol; epinephrine; Anti-IL-5-therapy; Eosinophilia; Exacerbation; mepolizumab; reproterol; sultamicillin plus sulbactam